SPARC licenses commercialisation rights of anti-epileptic drug to Tripoint Therapeutics
SPARC licenses commercialisation rights of anti-epileptic drug to Tripoint Therapeutics These tablets are indicated as adjunctive therapy for the treatment of partial onset seizures in patients 12 years of age and older. https://ift.tt/eA8V8J
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment